Haemolytic Uremic Syndrome Explained by UK Consultant Microbiologist Guide for FRCPath Part 2
A child with bloody diarrhoea, falling platelets and rising creatinine is not just an “acute gastroenteritis” case. It is a microbiology, nephrology, haematology and public health emergency until proven otherwise.
Haemolytic uremic syndrome, more commonly spelt haemolytic uraemic syndrome in UK practice, is a thrombotic microangiopathy defined by the triad of microangiopathic haemolytic anaemia, thrombocytopenia and acute kidney injury. For a Consultant Microbiologist, the key questions are practical and time-critical:
Is this Shiga toxin-producing Escherichia coli?
Could this be pneumococcal, complement-mediated or another secondary thrombotic microangiopathy?
What tests will confirm the diagnosis without delaying treatment?
What infection control and public health actions are needed today?
This article is educational and does not replace local clinical guidelines, specialist advice or urgent patient-specific management.
HUS is best understood as endothelial injury with platelet-rich microthrombi
The central event in HUS is injury to small-vessel endothelium. This triggers platelet activation, fibrin deposition and formation of microthrombi, particularly in the renal microvasculature.
Red cells passing through these narrowed, damaged vessels shear into fragments, seen as schistocytes or fragmented red cells on the blood film. Platelets are consumed in the thrombi, causing thrombocytopenia. The kidneys suffer from glomerular and arteriolar occlusion, causing acute kidney injury, haematuria, proteinuria and hypertension.
The laboratory pattern follows the biology:
Component of the syndrome | Mechanism | Typical findings |
Microangiopathic haemolytic anaemia | Mechanical red cell fragmentation in small vessels | Falling haemoglobin, schistocytes, raised LDH, low haptoglobin, raised unconjugated bilirubin |
Thrombocytopenia | Platelet consumption in microthrombi | Low platelet count, usually without severe spontaneous bleeding |
Acute kidney injury | Renal endothelial injury and microvascular occlusion | Rising creatinine, oliguria or anuria, haematuria, proteinuria, hypertension |
HUS sits within the wider group of thrombotic microangiopathies. This matters in exams and in real clinical practice because the differential includes thrombotic thrombocytopenic purpura, disseminated intravascular coagulation, malignant hypertension, pregnancy-related thrombotic microangiopathy and drug-induced disease.
The urgent adult differential is usually TTP. Severe ADAMTS13 deficiency, classically below 10% activity, supports TTP and prompts urgent plasma exchange. HUS, especially Shiga toxin-associated HUS, has different treatment priorities.
Shiga toxin-producing E. coli is the classic infectious cause
In the UK, the most tested infectious cause is Shiga toxin-producing E. coli, often abbreviated to STEC. Older terminology includes verocytotoxin-producing E. coli or VTEC. E. coli O157 is the best-known serogroup, but non-O157 STEC, such as O26 and others, also cause severe disease.
STEC infection commonly follows ingestion of a low infectious dose organism. Typical sources include:
Undercooked minced beef or other contaminated meat
Unpasteurised milk or dairy products
Contaminated salad, vegetables or water
Contact with farm animals or their environment
Person-to-person spread, especially in childcare settings or households
The incubation period is usually several days. Patients often develop abdominal pain and diarrhoea, which may become bloody. Fever may be absent or low-grade, a point that can help distinguish STEC from some invasive bacterial enteritides, although clinical overlap is common.
The major virulence factor is Shiga toxin, especially Stx2 in severe disease. The toxin binds globotriaosylceramide, also known as Gb3, on endothelial cells. It inhibits protein synthesis and promotes endothelial dysfunction, platelet activation and inflammatory injury. The renal endothelium is particularly vulnerable, which explains the kidney-predominant syndrome.
From a UK Consultant Microbiologist perspective, the practical message is simple: bloody diarrhoea plus evolving thrombocytopenia or renal impairment should trigger urgent stool testing for Shiga toxin genes and public health notification pathways.
Antibiotics in suspected STEC are not routine. Several observational studies have associated some antibiotics with increased risk of HUS, probably through toxin release or induction of Shiga toxin phage. The evidence varies by drug class and setting, but UK practice is cautious. Avoid antimotility agents in bloody diarrhoea because they may prolong toxin exposure and worsen ileus or colitis.
Other causes matter because treatment changes
Not all HUS is STEC-associated. In exams, a strong answer separates typical diarrhoea-associated HUS from atypical, pneumococcal and secondary forms.
Complement-mediated HUS is a diagnosis with major treatment implications
Complement-mediated HUS, often called atypical HUS, results from dysregulation of the alternative complement pathway. It may be genetic or acquired, including autoantibodies to factor H. Triggers such as infection, pregnancy or surgery may unmask the condition.
The presentation overlaps with STEC-HUS, but diarrhoeal prodrome may be absent, mild or misleading. Relapsing disease, family history, recurrence after renal transplantation or severe hypertension should raise suspicion.
Complement tests can support the diagnosis, but normal C3 or C4 does not exclude it. Specialist nephrology and haematology input is needed. Eculizumab, a monoclonal antibody against complement C5, has changed management for confirmed or strongly suspected complement-mediated HUS. Vaccination and antimicrobial prophylaxis against meningococcal disease are essential considerations because terminal complement blockade increases susceptibility to Neisseria meningitidis.
Pneumococcal HUS is uncommon but exam-relevant
Streptococcus pneumoniae-associated HUS typically occurs with invasive pneumococcal disease, such as pneumonia, empyema or meningitis. Pneumococcal neuraminidase exposes the Thomsen-Friedenreich antigen on red cells, platelets and endothelium.
This form is important because the direct antiglobulin test may be positive, unlike the usual DAT-negative pattern of microangiopathic haemolysis. Management focuses on treating invasive pneumococcal infection and supporting renal and haematological complications.
Secondary thrombotic microangiopathy has a broad differential
Secondary HUS-like thrombotic microangiopathy can occur with:
Pregnancy and postpartum states
Malignant hypertension
Solid organ or stem cell transplantation
Calcineurin inhibitors, quinine, gemcitabine and some other drugs
HIV and other infections
Autoimmune disease
Malignancy
For FRCPath Part 2, this differential matters because exam cases often provide partial information. A stem cell transplant recipient on ciclosporin with renal failure and thrombocytopenia is a different problem from a school-age child with bloody diarrhoea after a farm visit.
The clinical features follow the timeline of toxin injury
A typical STEC-HUS presentation evolves over days rather than hours.
The first phase is gastrointestinal. Patients develop cramping abdominal pain and diarrhoea. Bloody diarrhoea may develop after initial watery diarrhoea. Vomiting can occur. Fever is often absent or not prominent, although its absence does not confirm STEC.
The HUS phase often begins several days after diarrhoea starts. Key features include:
Pallor, fatigue or breathlessness from anaemia
Petechiae or bruising from thrombocytopenia
Reduced urine output
Dark urine, haematuria or proteinuria
Facial or peripheral oedema
Hypertension
Confusion, seizures or reduced consciousness in severe cases
Pancreatitis, hepatitis or cardiac involvement in complicated disease
Children are classically affected by STEC-HUS, but adults can develop severe disease, especially older adults or patients with comorbidity. Adult STEC-HUS may be complicated by diagnostic confusion with TTP or sepsis-associated DIC.
Clinical severity is driven by renal failure, fluid balance, neurological involvement and systemic complications. A patient can look deceptively well early in the diarrhoeal illness, then deteriorate quickly as thrombocytopenia and renal injury appear.
Diagnostic criteria combine clinical syndrome, haemolysis and renal injury
A practical diagnostic definition of HUS requires all three components:
Diagnostic component | Evidence to seek |
Microangiopathic haemolytic anaemia | Anaemia with schistocytes, raised LDH, low haptoglobin, indirect hyperbilirubinaemia, reticulocytosis |
Thrombocytopenia | Platelet count below the reference range, often moderate to severe |
Acute kidney injury | Rising creatinine, oliguria or anuria, haematuria, proteinuria, hypertension |
The diagnosis is clinical and laboratory based. Do not wait for stool culture or reference laboratory confirmation before escalating care if the triad is present.
Core investigations should be sent early
Initial tests should include:
Full blood count with platelet count
Blood film for red cell fragments
Urea, creatinine and electrolytes
Liver function tests, LDH, bilirubin and haptoglobin
Reticulocyte count
Coagulation screen
Direct antiglobulin test
Group and save or crossmatch
Urinalysis and urine protein assessment
Stool sample for STEC testing
Blood cultures if febrile, septic or invasive infection is suspected
The coagulation screen is usually normal or near-normal in HUS. Markedly prolonged PT, APTT, low fibrinogen and high D-dimer suggest DIC, although critically ill patients can have overlapping features.
Microbiology testing should target toxin, not just culture
Modern UK diagnostic pathways often use molecular testing for Shiga toxin genes, usually `stx1` and `stx2`, with culture and serotyping or whole genome sequencing pursued for public health investigation where relevant. A negative routine stool culture does not exclude STEC if toxin testing has not been done.
Specimens should be sent as early as possible because organism recovery falls with time. The laboratory should be told the clinical concern. “Bloody diarrhoea, query STEC-HUS” is far more useful than “MCS”.
When STEC is suspected or confirmed, the microbiology team should liaise with the local health protection team. STEC is a public health concern because of outbreaks, low infectious dose and person-to-person spread. Risk assessment is needed for food handlers, healthcare workers, nursery attendance and household contacts. Exclusion and clearance decisions should follow current UK health protection guidance.
Rule out close mimics at the same time
Tests for differential diagnosis may include:
Condition to exclude | Helpful test or clue |
TTP | ADAMTS13 activity, severe neurological features, very low platelet count, less prominent renal failure in classic cases |
DIC | Abnormal coagulation, low fibrinogen, sepsis, trauma or malignancy context |
Complement-mediated HUS | Complement studies, anti-factor H antibodies, genetic testing, recurrence or family history |
Pneumococcal HUS | Evidence of invasive pneumococcal disease, positive cultures or urinary antigen in the right context |
Autoimmune disease | ANA, dsDNA, antiphospholipid antibodies where clinically indicated |
Drug-induced thrombotic microangiopathy | Medication history, transplant drugs, chemotherapy, quinine exposure |
In an adult with thrombocytopenia and haemolysis, do not delay urgent haematology involvement while waiting for ADAMTS13 if TTP is plausible. That distinction is often tested in FRCPath scenarios.
Management depends on the cause, but supportive care is the foundation
HUS management is multidisciplinary. Microbiology supports diagnosis, antimicrobial decisions, infection control and public health action. Nephrology leads kidney support and fluid management. Haematology helps distinguish TTP and other thrombotic microangiopathies. Paediatrics or adult acute medicine coordinate overall care.
STEC-HUS needs careful supportive management
There is no proven toxin-neutralising treatment in routine UK practice for STEC-HUS. Care focuses on preventing complications while the endothelial injury resolves.
Core measures include:
Careful fluid assessment and correction of dehydration early in diarrhoeal illness
Avoidance of fluid overload once oliguric renal failure develops
Close monitoring of electrolytes, especially potassium
Blood pressure control
Red cell transfusion for symptomatic or severe anaemia
Dialysis or haemofiltration when indicated
Nutritional support
Monitoring for neurological, pancreatic and cardiac complications
Platelet transfusion is usually avoided unless there is life-threatening bleeding or an invasive procedure with significant bleeding risk. The thrombocytopenia reflects consumption, and transfused platelets may theoretically contribute to microthrombi.
Antimotility agents should be avoided. Antibiotics are generally avoided in suspected or confirmed STEC unless there is another compelling indication, such as sepsis from a different source. If antibiotics have already been given, document the exposure and focus on supportive care.
Infection prevention measures should start before confirmation
Suspected STEC diarrhoea requires enteric precautions. Practical steps include:
Single room isolation where possible
Gloves and apron for contact with faeces or contaminated surfaces
Soap and water hand hygiene, especially when spores or heavy soiling are possible
Environmental cleaning with locally approved disinfectants
Clear advice for household hygiene
Alcohol gel alone is not enough after visible faecal contamination. The low infectious dose of STEC makes meticulous hygiene essential.
The health protection team will advise on exclusion from work, school or nursery and on clearance sampling for high-risk groups. This should be documented clearly because discharge advice is a common weak point in real cases and exam answers.
Complement-mediated HUS requires early specialist therapy
When complement-mediated HUS is suspected, early expert discussion is essential. Eculizumab may be indicated after specialist assessment. Because it blocks terminal complement, patients need meningococcal vaccination and often antibiotic prophylaxis according to local and national guidance.
Plasma exchange was historically used in atypical HUS and may still appear in examinations, especially where TTP cannot initially be excluded. Current practice is more targeted, with complement blockade central to confirmed complement-mediated disease.
Pneumococcal HUS needs treatment of invasive infection
For pneumococcal HUS, management includes appropriate antimicrobial therapy for invasive pneumococcal disease, drainage of empyema if present, renal support and cautious transfusion support. DAT positivity can complicate transfusion testing, so early blood bank involvement helps.
The microbiologist’s role is diagnostic, advisory and public health focused
A Consultant Microbiologist adds value at several points.
The first is test selection. The right stool test must be requested early, and the laboratory needs enough clinical detail to prioritise STEC testing. Where a local syndromic PCR panel is used, know whether it includes `stx1` and `stx2`. If not, arrange specific testing.
The second is antimicrobial advice. A common clinical question is whether to give ciprofloxacin or another agent for bloody diarrhoea. In suspected STEC, the safer default is to avoid antibiotics unless another diagnosis or syndrome demands treatment. If the patient is septic, immunocompromised or has travel-related dysentery, the decision becomes more nuanced and should be documented.
The third is infection control. Cases may involve nurseries, farms, food premises or care homes. A microbiologist should think beyond the index patient. The relevant questions include:
Has the patient attended childcare, healthcare work or food handling while symptomatic?
Are household contacts symptomatic?
Was there farm exposure, unpasteurised dairy or a shared meal?
Does the case fit a wider outbreak signal?
Has the health protection team been informed?
The fourth is interpretation. Finding STEC in stool supports STEC-HUS, but the patient still needs monitoring for complications. Not finding STEC does not end the case if the sample was late or incomplete. Persisting thrombotic microangiopathy should prompt evaluation for complement-mediated and secondary causes.
Common examination traps are predictable
FRCPath Medical Microbiology Part 2 often tests how candidates reason under practical pressure. HUS is well suited to OSPEs, ward referrals, laboratory results interpretation and infection control stations.
Do not treat all bloody diarrhoea the same
A febrile traveller with dysentery after South Asia raises concern for Shigella, Campylobacter, amoebiasis and other pathogens. A child with severe abdominal pain, bloody diarrhoea, no fever and a farm visit raises STEC concern. Both need stool testing, but antibiotic advice differs.
For STEC, mention the risk of HUS and the need to avoid antimotility agents. State that antibiotics are not routinely recommended while STEC is suspected.
Do not forget public health notification
A technically correct answer that omits public health action is incomplete. STEC has outbreak potential and specific implications for nurseries, food handlers and healthcare workers. In a UK exam, say that suspected or confirmed STEC should be discussed with the local health protection team according to local reporting pathways.
Do not confuse HUS with TTP
Both cause microangiopathic haemolytic anaemia and thrombocytopenia. TTP is classically linked to severe ADAMTS13 deficiency and is a haematological emergency requiring urgent plasma exchange. HUS has more prominent renal involvement, especially in STEC-HUS, but adult presentations overlap.
A safe exam answer says:
Send ADAMTS13 urgently if TTP is possible.
Involve haematology early.
Do not delay life-saving TTP treatment if clinically indicated.
Continue microbiological investigation for STEC where there is diarrhoea or exposure history.
Do not rely on routine culture alone
Routine culture may miss non-O157 STEC if toxin testing is not performed. Good answers specify Shiga toxin gene testing or toxin detection as well as culture and reference typing. In the UK, confirmatory typing and outbreak investigation often involve reference laboratory pathways and public health teams.
Do not ignore complement-mediated HUS
If there is no diarrhoeal prodrome, if STEC testing is negative, if disease is recurrent, or if renal injury is severe and persistent, consider complement-mediated HUS. Mention complement studies, anti-factor H antibodies and specialist nephrology input. Eculizumab is a key management point.
A focused revision framework helps for FRCPath Part 2
A useful way to revise HUS is to build a short, repeatable answer structure. In a viva or written station, this keeps the response clinical rather than theoretical.
Start with the syndrome
Define HUS as:
Microangiopathic haemolytic anaemia, thrombocytopenia and acute kidney injury due to thrombotic microangiopathy.
Then give the likely cause from the stem. If there is bloody diarrhoea or outbreak exposure, say STEC until proven otherwise. If there is invasive pneumococcal disease, mention pneumococcal HUS. If there is recurrence, transplant history or no diarrhoeal trigger, raise complement-mediated or secondary thrombotic microangiopathy.
Ask for the missing clinical details
High-yield questions include:
Onset and duration of diarrhoea
Presence of blood in stool
Fever and abdominal pain
Farm, animal, food, water or travel exposure
Nursery, school, healthcare or food-handling role
Household or cluster illness
Drug history, including quinine, chemotherapy and calcineurin inhibitors
Pregnancy or postpartum status
Transplant history
Past episodes or family history
State the immediate tests
For a suspected STEC-HUS case, list:
FBC and blood film
Urea, creatinine and electrolytes
LDH, bilirubin, haptoglobin and reticulocytes
Coagulation screen
DAT
Stool for Shiga toxin PCR or toxin testing, culture and typing
Urinalysis
ADAMTS13 if TTP is in the differential
Complement studies if atypical HUS is possible
Give practical management
A concise management answer should include:
Admit under paediatrics or adult medicine with nephrology input
Monitor fluid balance, urine output, blood pressure and electrolytes
Avoid antimotility agents
Avoid routine antibiotics in suspected STEC
Provide renal replacement therapy when indicated
Transfuse red cells if clinically needed
Avoid platelet transfusion unless bleeding or procedure-related need
Use enteric precautions
Notify or discuss with health protection team
Consider complement-mediated HUS and eculizumab with specialists when appropriate
Know the specimen and laboratory detail
Part 2 candidates are expected to understand the lab pathway. Be ready to explain that stool should be sent promptly, with clear clinical details. The request should make STEC suspicion explicit. Testing should detect Shiga toxin or toxin genes, not just common bacterial pathogens.
For O157, culture characteristics on selective media are historically important, but modern UK diagnosis increasingly relies on molecular detection and reference typing. Do not make your answer depend on sorbitol non-fermentation alone, because non-O157 STEC will be missed by that mental shortcut.
Sources and guidance worth revising
For exam preparation and safe UK practice, revise from recognised sources rather than isolated review notes. Useful sources include:
UK Health Security Agency guidance on STEC and gastrointestinal infection control
Local laboratory SOPs for faeces testing and Shiga toxin detection
National or regional paediatric nephrology guidance on HUS
British Society for Haematology material on thrombotic microangiopathies and TTP pathways
Renal association or nephrology guidance on complement-mediated HUS and eculizumab pathways
Standard medical microbiology texts covering STEC, Shigella dysenteriae type 1 and invasive pneumococcal disease
The key is to connect microbiology with the clinical syndrome. HUS is not just a list of organisms. It is a pattern of endothelial injury where the cause determines infection control, antimicrobial advice, public health response and specialist treatment.
The essential takeaway
HUS should trigger a structured response. Recognise the triad, confirm microangiopathic haemolysis, assess renal severity, test promptly for STEC, and involve nephrology, haematology and public health early.
For FRCPath Medical Microbiology Part 2, the highest-scoring answers are practical. State the likely cause, request the right tests, avoid harmful treatment in suspected STEC, remember infection control, and keep a broad thrombotic microangiopathy differential when the story does not fit classic diarrhoea-associated disease.
Comments